Last Updated: November 16, 2026

Investigational Drug Information for Peficitinib

« Back to Dashboard


What is the development status for investigational drug Peficitinib?

Peficitinib is an investigational drug.

There have been 14 clinical trials for Peficitinib. The most recent clinical trial was a Phase 3 trial, which was initiated on August 8th 2014.

The most common disease conditions in clinical trials are Arthritis, Arthritis, Rheumatoid, and Psoriasis. The leading clinical trial sponsors are Astellas Pharma Inc, Astellas Pharma Global Development, Inc., and Astellas Pharma China, Inc.

Recent Clinical Trials for Peficitinib
TitleSponsorPhase
A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese SubjectsAstellas Pharma China, Inc.Phase 1
A Study to Assess Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)Astellas Pharma China, Inc.Phase 3
A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and MetforminAstellas Pharma IncPhase 1

See all Peficitinib clinical trials

Clinical Trial Summary for Peficitinib

Top disease conditions for Peficitinib
Top clinical trial sponsors for Peficitinib

See all Peficitinib clinical trials

Peficitinib Development Update and Market Projection

Last updated: November 9, 2026

Peficitinib is an oral Janus kinase inhibitor developed by Astellas Pharma for rheumatoid arthritis. It is marketed in Japan under the brand name Smyraf and has also received approval in South Korea. The drug has not obtained FDA or European Commission marketing authorization. Its commercial opportunity is limited to selected Asian markets, with material constraints from crowded JAK inhibitor competition, rheumatoid arthritis safety requirements, and the absence of a broad Western regulatory footprint.

What is the current development status of peficitinib?

Peficitinib, also known as ASP015K, is an oral small-molecule JAK inhibitor with activity against JAK1, JAK2, JAK3 and TYK2. Its clinical development focused primarily on rheumatoid arthritis in patients who had inadequate responses to conventional disease-modifying antirheumatic drugs or biologic therapies.

Item Status
Active ingredient Peficitinib
Original developer Astellas Pharma
Brand Smyraf
Primary indication Rheumatoid arthritis
Dosage form Oral tablets
Japan approval March 2019
South Korea approval Approved for rheumatoid arthritis
United States No FDA approval
European Union No European Commission approval
Main development region Japan and other Asian markets
Commercial position Regional JAK inhibitor

Japan approved peficitinib in March 2019 for rheumatoid arthritis in patients who had an inadequate response to conventional treatments. The approved regimen is generally 150 mg once daily, with a 100 mg once-daily option used in patients requiring dose reduction or with greater safety considerations.[1]

Peficitinib was evaluated in the RAJ clinical program, which included Japanese and other Asian patients with active rheumatoid arthritis. Phase 3 studies reported improvements in American College of Rheumatology response measures and disease activity scores compared with placebo in patients receiving background methotrexate or other conventional therapies.[2-4]

When did peficitinib receive regulatory approval?

Peficitinib first reached the market in Japan in 2019. South Korea subsequently authorized the product for rheumatoid arthritis. No public regulatory milestone has established the drug as an approved product in the United States, European Union, Canada or Australia.

FDA regulatory status

Peficitinib is not an FDA-approved rheumatoid arthritis treatment. It therefore has:

  • No U.S. approved label.
  • No U.S. commercial launch.
  • No U.S. Orange Book-listed reference product.
  • No U.S. Hatch-Waxman generic pathway tied to an approved peficitinib product.
  • No FDA-recognized U.S. market exclusivity period attached to a marketed peficitinib product.

The absence of U.S. approval materially reduces the drug's global revenue ceiling. It also means that the product is not directly exposed to U.S. Paragraph IV litigation or an Abbreviated New Drug Application launch based on a U.S. reference listing.

Japan regulatory status

Japan is the core commercial market. The approval was based on the RAJ development program and supported use in adults with rheumatoid arthritis who had inadequate responses to conventional synthetic disease-modifying antirheumatic drugs.

Astellas has marketed Smyraf in Japan. Japanese reimbursement and pricing decisions, rather than U.S. patent exclusivity, determine most of the product's commercial economics.

What clinical evidence supports peficitinib?

Peficitinib produced statistically significant efficacy results in phase 3 rheumatoid arthritis studies, but its clinical differentiation from other oral JAK inhibitors is limited.

Reported development findings included:

  • Improved ACR20, ACR50 and ACR70 response rates compared with placebo.
  • Reduction in disease activity in patients with inadequate response to conventional DMARDs.
  • Efficacy in patients with prior methotrexate exposure.
  • Support for once-daily oral administration.
  • Safety findings consistent with the broader JAK inhibitor class, including infection, herpes zoster, laboratory abnormalities and lipid changes.

The principal commercial issue is not whether peficitinib has rheumatoid arthritis activity. It does. The issue is whether it offers a sufficiently differentiated benefit against established alternatives such as tofacitinib, baricitinib, upadacitinib and biologic therapies.

JAK inhibitors are subject to class-level safety concerns involving serious infections, malignancies, major adverse cardiovascular events and thrombosis. The FDA required boxed-warning changes for certain JAK inhibitors after the ORAL Surveillance trial involving tofacitinib. Although peficitinib is not FDA approved, the same class-level safety concerns affect prescribing, labeling discussions and physician adoption in markets where it is available.[5]

What formulations are protected by peficitinib development rights?

The marketed product is an immediate-release oral tablet. Public clinical and regulatory materials do not establish a commercially meaningful portfolio of differentiated formulations such as extended-release tablets, injectable delivery systems or fixed-dose combinations.

The principal product attributes are:

  • Immediate-release tablet delivery.
  • Once-daily dosing.
  • 100 mg and 150 mg strength options.
  • Oral administration for chronic rheumatoid arthritis treatment.

There is no established public evidence that a new formulation, pediatric product or combination product will extend peficitinib's commercial life materially.

What patents protect peficitinib?

Peficitinib has been the subject of international patent filings covering the active compound, pharmaceutical compositions and therapeutic use. The practical strength of that estate depends on the jurisdiction, claim scope, prosecution history, patent-term adjustments and any later national invalidity or opposition proceedings.

A complete patent-by-patent expiration analysis cannot be stated reliably from the public regulatory record alone. The drug also does not have a U.S. Orange Book patent listing because it lacks FDA approval.

Patent and exclusivity issue Assessment
U.S. Orange Book listing None identified for an FDA-approved peficitinib product
U.S. Paragraph IV risk Not applicable to a marketed U.S. reference product
Japan patent protection Potentially relevant, but individual national claims require registry-level review
Formulation patent risk No publicly established commercial formulation moat
Method-of-use protection Possible in national filings, with practical value constrained by the limited indication
Manufacturing protection Compound synthesis and process claims may affect API sourcing
Biosimilar exposure Not applicable; peficitinib is a small molecule
Generic exposure Relevant in Japan and South Korea after applicable patent and regulatory barriers expire

Because peficitinib is a small molecule, its long-term competitive risk comes from conventional generic substitution rather than biosimilars. Process patents may delay or complicate API entry, but they generally provide a weaker commercial barrier than a valid composition-of-matter patent.

When does peficitinib lose exclusivity?

The commercial loss of exclusivity will vary by country because Japan and South Korea apply separate patent, data-protection and reimbursement rules. The first Japanese approval occurred in 2019, but approval date alone does not establish the final generic-entry date.

The principal timing factors are:

  1. Expiration of valid compound and use patents.
  2. Any patent-term adjustment or extension.
  3. Regulatory data-protection periods.
  4. National generic approval requirements.
  5. Challenges to patents covering the active pharmaceutical ingredient.
  6. Government price revisions before generic entry.

No U.S. exclusivity timeline is relevant because peficitinib has not been approved by the FDA. No U.S. Paragraph IV challenge or settlement agreement is publicly associated with an FDA-listed peficitinib reference product.

What patent litigation affects peficitinib?

No major publicly documented U.S. patent litigation campaign has been associated with peficitinib. The product's litigation profile is narrower than that of widely marketed JAK inhibitors such as Xeljanz, Olumiant and Rinvoq.

The absence of major U.S. litigation reflects the lack of U.S. approval and commercial sales rather than proof that all foreign patent risks have been eliminated. Japanese and Korean patent disputes, if any, would be more relevant to actual market access and should be assessed through national court and patent-office records.

How strong is the peficitinib patent estate?

The patent estate is commercially moderate rather than strong on a global basis.

Factors supporting patent strength

  • The active compound was protected through international pharmaceutical patent filings.
  • The drug has a defined chemical entity rather than a repurposed generic compound.
  • Composition-of-matter claims can provide meaningful protection where valid and unexpired.
  • Manufacturing and process claims may increase the cost of generic API development.

Factors limiting patent strength

  • No U.S. approval or Orange Book listing.
  • No broad Western commercial footprint.
  • Limited evidence of a differentiated formulation franchise.
  • Small-molecule generic substitution remains structurally feasible.
  • The principal indication is crowded and subject to rapid therapeutic substitution.
  • Regional approval limits the value of global patent coverage.

Peficitinib's regulatory footprint is more important than its nominal number of patent filings. A patent estate covering Japan and South Korea can protect a regional product, but it cannot create the revenue scale available from U.S. and European authorization.

Which companies compete with peficitinib?

Peficitinib competes with both JAK inhibitors and biologic rheumatoid arthritis therapies.

Competitor Company Class Commercial relevance
Tofacitinib Pfizer JAK inhibitor Established oral competitor
Baricitinib Eli Lilly and Incyte JAK inhibitor Strong rheumatoid arthritis presence in multiple markets
Upadacitinib AbbVie JAK inhibitor High-efficacy oral competitor with broad immunology expansion
Filgotinib Galapagos and partner markets JAK inhibitor Regional competitor with differentiated regulatory history
Tocilizumab Roche/Chugai IL-6 receptor inhibitor Established biologic alternative
Sarilumab Sanofi and Regeneron IL-6 receptor inhibitor Injectable biologic competitor
Adalimumab AbbVie and biosimilar manufacturers TNF inhibitor Large established class with broad substitution
Methotrexate Generic manufacturers Conventional DMARD First-line treatment and payer control

Upadacitinib and baricitinib are particularly important commercial comparators because they combine oral administration with broader international availability. Tofacitinib has greater brand recognition and physician familiarity. Low-cost biosimilar TNF inhibitors also limit the willingness of payers to reimburse a regional JAK inhibitor at a premium.

What is the market projection for peficitinib?

Peficitinib is likely to remain a low-to-moderate revenue product concentrated in Japan and South Korea. Its market is unlikely to support a global blockbuster profile without new approvals, label expansion or a strong clinical differentiation claim.

Base-case projection

The following projection is a market model based on regional access, class competition and likely generic pressure. It is not company guidance.

Year Base-case global sales Downside case Upside case
2025 $25 million $15 million $40 million
2026 $27 million $14 million $45 million
2027 $28 million $12 million $48 million
2028 $27 million $10 million $48 million
2029 $25 million $8 million $45 million

The modeled base case assumes:

  • Japan remains the dominant market.
  • South Korean sales remain smaller than Japanese sales.
  • No U.S. or European launch occurs.
  • JAK class safety restrictions continue to influence prescribing.
  • Upadacitinib, baricitinib and tofacitinib retain strong competitive positions.
  • Generic entry or price erosion begins in at least one major regional market during the forecast period.
  • No major new indication is added.

Under this model, cumulative sales from 2025 through 2029 are approximately $132 million in the base case, compared with $59 million in the downside case and $226 million in the upside case.

Revenue exposure

The economic exposure is primarily regional:

  • Japan: approximately 75% to 90% of commercial revenue.
  • South Korea: approximately 10% to 20%.
  • Other markets: limited or immaterial unless additional approvals occur.

The highest-value commercial event would be a new approval in a major Western market, but the available public development record does not support treating that outcome as the base case. Label expansion into psoriatic arthritis, ulcerative colitis, atopic dermatitis or other immune-mediated diseases would also be required to materially change the forecast.

What generic launch risks exist for peficitinib?

Generic-entry risk is moderate to high over the medium term.

The main risk factors are:

  • Small-molecule chemistry that can be reproduced by generic manufacturers.
  • Absence of a biologic manufacturing barrier.
  • Limited formulation differentiation.
  • Concentrated regional sales that make price competition visible quickly.
  • Established alternative JAK inhibitors that can absorb switching demand.
  • Potential national price cuts before patent expiry.

Manufacturing barriers may delay entry if the original sponsor retains difficult process know-how or if active-ingredient specifications are demanding. Those barriers are unlikely to prevent eventual generic competition if core composition and use protections expire.

How does peficitinib compare with other JAK inhibitors?

Peficitinib's main advantage is oral once-daily administration in an approved rheumatoid arthritis population. Its disadvantages are narrower geographic approval, lower commercial visibility and limited evidence of a differentiated efficacy or safety profile.

Attribute Peficitinib Upadacitinib Baricitinib Tofacitinib
Oral dosing Yes Yes Yes Yes
Major Western approval No Yes Yes Yes
Rheumatoid arthritis use Yes Yes Yes Yes
Broad multi-indication platform Limited Strong Moderate Strong
Global commercial scale Limited High High High
U.S. Orange Book relevance None Yes Yes Yes
Biosimilar risk None None None None
Generic risk Regional Future risk Future risk Future risk

Key Takeaways

  • Peficitinib is an approved oral rheumatoid arthritis treatment in Japan and South Korea.
  • Astellas is the principal developer and commercial sponsor associated with Smyraf.
  • The product has no FDA or European Union marketing authorization.
  • No U.S. Orange Book listing or U.S. Paragraph IV litigation is associated with peficitinib.
  • Its market is concentrated in Japan, with South Korea providing a smaller contribution.
  • The drug lacks a clearly differentiated clinical or formulation position against other JAK inhibitors.
  • A reasonable 2025-2029 sales range is approximately $59 million to $226 million cumulatively, with a base case near $132 million.
  • Generic competition, JAK class safety concerns and regional approval limits cap the long-term commercial opportunity.
  • Biosimilar risk is irrelevant because peficitinib is a small molecule; generic API and finished-dose competition are the principal threats.

FAQs

Is peficitinib approved in the United States?

No. Peficitinib has not received FDA approval and is not marketed in the United States.

Is peficitinib a biosimilar?

No. Peficitinib is a chemically synthesized small-molecule JAK inhibitor. Future competition would come from generic versions, not biosimilars.

What is the brand name for peficitinib?

The brand name is Smyraf. It is marketed primarily in Japan and has also been approved in South Korea.

Can peficitinib be used for ulcerative colitis or atopic dermatitis?

The established commercial indication is rheumatoid arthritis. There is no broad approved multi-indication franchise comparable with several competing JAK inhibitors.

Is peficitinib a strong licensing asset?

Its licensing value is regional and indication-specific. The asset may have value in Japan, South Korea or selected Asian markets, but the absence of U.S. and European approval substantially limits global partnering economics.

References

  1. Pharmaceuticals and Medical Devices Agency. (2019). Review report: Peficitinib hydrobromide, Smyraf tablets. Tokyo, Japan: PMDA.

  2. Takeuchi, T., Tanaka, Y., Iwasaki, M., et al. (2016). Efficacy and safety of peficitinib in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled phase 2b study. Arthritis Research & Therapy, 18, 287.

  3. Genovese, M. C., Greenwald, M., Codding, C., et al. (2018). Peficitinib, a JAK inhibitor, in patients with rheumatoid arthritis and inadequate response to conventional DMARDs. Arthritis & Rheumatology, 70(5), 679-688.

  4. Astellas Pharma Inc. (2019). Smyraf tablets: Japanese prescribing information. Tokyo, Japan: Astellas Pharma.

  5. U.S. Food and Drug Administration. (2021). FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots and death for JAK inhibitors that treat certain chronic inflammatory conditions. Silver Spring, MD: FDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.